Genome‐wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis

Background: DNA methylation alterations are early events in tumorigenesis and important in the regulation of gene expression in cancer cells. Lung cancer patients have in general a poor prognosis, and a deeper insight into the epigenetic landscape in lung adenocarcinoma tumors and its prognostic implications is needed.

[1]  R. Herbst,et al.  Lung Cancer in the Era of Precision Medicine , 2015, Clinical Cancer Research.

[2]  Janakiraman Subramanian,et al.  Lung cancer in never smokers: a review. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Jinming Li,et al.  Large Intervening Non-Coding RNA HOTAIR Is an Indicator of Poor Prognosis and a Therapeutic Target in Human Cancers , 2014, International journal of molecular sciences.

[4]  M. Grce,et al.  Genome-wide DNA methylation assay reveals novel candidate biomarker genes in cervical cancer , 2013, Epigenetics.

[5]  Pan‐Chyr Yang,et al.  Dysregulation of p53/Sp1 control leads to DNA methyltransferase-1 overexpression in lung cancer. , 2010, Cancer research.

[6]  T. Hampton,et al.  The Cancer Genome Atlas , 2020, Indian Journal of Medical and Paediatric Oncology.

[7]  C. Atalay.  Epigenetics in breast cancer. , 2013, Experimental oncology.

[8]  M. Colonna,et al.  TREM-1 amplifies inflammation and is a crucial mediator of septic shock , 2001, Nature.

[9]  Arnoldo Frigessi,et al.  Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis , 2014, Genome Biology.

[10]  P. Grambsch,et al.  A Package for Survival Analysis in S , 1994 .

[11]  Steven Piantadosi,et al.  DNA methylation markers and early recurrence in stage I lung cancer. , 2008, The New England journal of medicine.

[12]  Ming Xiao,et al.  Dimethyl Sulfoxide Damages Mitochondrial Integrity and Membrane Potential in Cultured Astrocytes , 2014, PloS one.

[13]  P. Laird.  Early detection: The power and the promise of DNA methylation markers , 2003, Nature Reviews Cancer.

[14]  Jyh‐cherng Yu,et al.  The prognostic significance of RUNX2 and miR-10a/10b and their inter-relationship in breast cancer , 2014, Journal of Translational Medicine.

[15]  B. Boman,et al.  HOX genes and their role in the development of human cancers , 2014, Journal of Molecular Medicine.

[16]  S. Zöchbauer-Müller,et al.  Lung cancer: From single-gene methylation to methylome profiling , 2010, Cancer and Metastasis Reviews.

[17]  Xueyan Zhong,et al.  High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer , 2008, Proceedings of the National Academy of Sciences.

[18]  Robert Tibshirani,et al.  SAM “Significance Analysis of Microarrays” Users guide and technical document , 2002 .

[19]  Arnoldo Frigessi,et al.  BIOINFORMATICS ORIGINAL PAPER doi:10.1093/bioinformatics/btm305 Gene expression Predicting survival from microarray data—a comparative study , 2022 .

[20]  M. Esteller,et al.  A prognostic DNA methylation signature for stage I non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[22]  Johan Staaf,et al.  Genome-wide DNA Methylation Analysis of Lung Carcinoma Reveals One Neuroendocrine and Four Adenocarcinoma Epitypes Associated with Patient Outcome , 2014, Clinical Cancer Research.

[23]  Andres Metspalu,et al.  Methylation Markers of Early-Stage Non-Small Cell Lung Cancer , 2012, PloS one.

[24]  Hsuan-Yu Chen,et al.  TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancer. , 2008, American journal of respiratory and critical care medicine.

[25]  Peter A. Jones,et al.  Epigenetics in cancer. , 2010, Carcinogenesis.

[26]  Jing Liu,et al.  The long non-coding RNA HOTAIR indicates a poor prognosis and promotes metastasis in non-small cell lung cancer , 2013, BMC Cancer.

[27]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[28]  Yi-long Wu,et al.  Targeting mTOR to Overcome Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer Cells , 2013, PloS one.

[29]  M. Benito,et al.  Methylation profiling in non-small cell lung cancer: clinical implications. , 2011, International journal of oncology.

[30]  Hidemi Ito,et al.  Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma. , 2012, Carcinogenesis.

[31]  Carlos Caldas,et al.  TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance , 2014, Clinical Cancer Research.

[32]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[33]  R. Tibshirani.  Regression Shrinkage and Selection via the Lasso , 1996 .

[34]  P. Jänne,et al.  Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M. , 2014, Cell reports.

[35]  Robert M. Roman,et al.  TREM-1 Is Induced in Tumor Associated Macrophages by Cyclo-Oxygenase Pathway in Human Non-Small Cell Lung Cancer , 2014, PloS one.

[36]  J. Minna,et al.  Smoke exposure, histologic type and geography‐related differences in the methylation profiles of non‐small cell lung cancer , 2003, International journal of cancer.

[37]  Vessela Kristensen,et al.  Methylation profiling with a panel of cancer related genes: Association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer , 2011, Molecular oncology.

[38]  Yi-long Wu,et al.  Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors , 2012, Cancer Chemotherapy and Pharmacology.

[39]  N. George,et al.  Effect of cigarette smoke condensate on gene promoter methylation in human lung cells , 2014, Tobacco induced diseases.

[40]  M. Colonna,et al.  TREM-1 (triggering receptor expressed on myeloid cells): a new player in acute inflammatory responses. , 2003, The Journal of infectious diseases.

[41]  Sébastien Couraud,et al.  Lung cancer in never smokers--a review. , 2012, European journal of cancer.

[42]  N. Ahuja,et al.  Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[43]  G. Lang,et al.  Genome-wide CpG island methylation analyses in non-small cell lung cancer patients. , 2013, Carcinogenesis.

[44]  Youngchul Kim,et al.  Microarray analysis of gene expression in lung cancer cell lines treated by fractionated irradiation. , 2014, Anticancer research.

[45]  A. Riggs,et al.  Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay , 2007, Proceedings of the National Academy of Sciences.

[46]  R. Jaenisch,et al.  Induction of Tumors in Mice by Genomic Hypomethylation , 2003, Science.

[47]  C. Livingstone.  IGF2 and cancer. , 2013, Endocrine-related cancer.

[48]  Zhifu Sun,et al.  DNA methylation and RNA expression profiles in lung adenocarcinomas of never-smokers. , 2015, Cancer genetics.

[49]  A. Børresen-Dale,et al.  Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas , 2014, International journal of cancer.

[50]  A. Lenzi,et al.  PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer. , 2013, Endocrine-related cancer.

[51]  Boris Lenhard,et al.  Genome-wide DNA methylation profiling of non-small cell lung carcinomas , 2012, Epigenetics & Chromatin.

[52]  F. Fuks,et al.  Exposing the DNA methylome iceberg. , 2011, Trends in biochemical sciences.

[53]  Alfonso Valencia,et al.  Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia , 2012, Nature Genetics.

[54]  F. Entschladen,et al.  Cell Communication and Signaling BioMed Central Review Extravasation of leukocytes in comparison to tumor cells , 2008 .

[55]  P. Rao,et al.  Galectin‐4 functions as a tumor suppressor of human colorectal cancer , 2011, International journal of cancer.

[56]  C. Livingstone.  IGF2 and cancer. , 2013, Endocrine-related cancer.

[57]  M. Rocchi,et al.  A novel fusion 5′AFF3/3′BCL2 originated from a t(2;18)(q11.2;q21.33) translocation in follicular lymphoma , 2008, Oncogene.

[58]  T. Rauch,et al.  DNA methylation patterns in lung carcinomas. , 2009, Seminars in cancer biology.

[59]  J. Tost,et al.  Complete pipeline for Infinium(®) Human Methylation 450K BeadChip data processing using subset quantile normalization for accurate DNA methylation estimation. , 2012, Epigenomics.

[60]  H. Pass,et al.  Aryl hydrocarbon receptor and lung cancer. , 2013, Anticancer research.

[61]  Giovanni Tesoriere,et al.  RB1 in cancer: Different mechanisms of RB1 inactivation and alterations of pRb pathway in tumorigenesis , 2013, Journal of cellular physiology.

[62]  S. Lam,et al.  Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression , 2012, Genome research.